Lesson plan

APA-01

APA-01, also known as PharmAla-1, is an entactogen of the phenethylamine, amphetamine, and MDxx families related to MDMA which is under development for potential medical use. It is a cyclized phenethylamine and is a derivative of MDMA in which the α position has been cyclized with the amine via a propyl group to form a pyrrolidine ring. The drug is predicted to interact with the monoamine transporters and with the serotonin 5-HT 2 receptors. In contrast to MDMA, it does not produce hyperthermia in rodents, instead producing dose-dependent hypothermia. In addition, unlike MDMA, neither APA-01 nor the corresponding (S)- enantiomer showed hyperlocomotion in rodents. Both APA-01 and the (S)- enantiomer produced sympathomimetic cardiovascular effects in rodents, but APA-01 had reduced impact compared to the (S)- enantiomer and relative to MDMA and dextromethamphetamine. APA-01 showed prosocial effects in rodents similarly to MDMA, but with greater potency. The drug is said to have improved safety compared to MDMA. The chemical synthesis of APA-01 has been described. APA-01 is under development by PharmAla Biotech. As of April 2026, it is in the preclinical research stage of development. Possible medical applications of APA-01 include treatment of post-traumatic stress disorder (PTSD) and neurological conditions like traumatic brain injury (TBI) and stroke.…

Back to article

Article summary

APA-01, also known as PharmAla-1, is an entactogen of the phenethylamine, amphetamine, and MDxx families related to MDMA which is under development for potential medical use. It is a cyclized phenethylamine and is a derivative of MDMA in which the α position has been cyclized with the amine via a propyl group to form a pyrrolidine ring. The drug is predicted to interact with the monoamine transporters and with the serotonin 5-HT 2 receptors. In contrast to MDMA, it does not produce hyperthermia in rodents, instead producing dose-dependent hypothermia. In addition, unlike MDMA, neither APA-01 nor the corresponding (S)- enantiomer showed hyperlocomotion in rodents. Both APA-01 and the (S)- enantiomer produced sympathomimetic cardiovascular effects in rodents, but APA-01 had reduced impact compared to the (S)- enantiomer and relative to MDMA and dextromethamphetamine. APA-01 showed prosocial effects in rodents similarly to MDMA, but with greater potency. The drug is said to have improved safety compared to MDMA. The chemical synthesis of APA-01 has been described. APA-01 is under development by PharmAla Biotech. As of April 2026, it is in the preclinical research stage of development. Possible medical applications of APA-01 include treatment of post-traumatic stress disorder (PTSD) and neurological conditions like traumatic brain injury (TBI) and stroke.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.